Navigation Links
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/10/2013

SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 15th at 1 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jacobs Automotive, a group of car dealerships headquartered in ... Blood Center and offering free oil change coupons for participation ... Jan. 18 at the Bill Jacobs Cadillac and Chevrolet location ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto annual ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Therapeutics, Inc.,(Nasdaq: TPTX ) today announced that ... in certain royalty amounts that may become payable to ... and tezampanel,should either or both gain regulatory approval. Specifically, ... points and the middle tier,royalty rate will be reduced ...
... Pa., Nov. 25 Tengion Inc., a clinical stage regenerative medicine ... that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, ... Tuesday, December 2, 2008 at 9:50 a.m. EST at The Palace ... , About Tengion , ...
... 25 /PRNewswire-Asia/ -- ScinoPharm, an active,pharmaceutical ingredient (API) ... 7,435,818 entitled "Novel Crystal Forms of Irinotecan,Hydrochloride." The ... hydrochloride and processes for their preparation as well ... of treating,metastatic carcinoma of the colon or rectum ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2ScinoPharm Granted US Patent for Novel Crystal Forms 2
(Date:4/20/2014)... Mothers give a newborn baby a gift of ... system. But antibiotics, used to fend off infection, ... leaving already-vulnerable premature babies more susceptible to dangerous ... neonatology researchers at The Children,s Hospital of Philadelphia ... revealing how gut microbes play a crucial role ...
(Date:4/18/2014)... decades, scientists have used techniques like X-ray crystallography and ... into the atomic structure of molecules, but such efforts ... demand large quantities of a specific molecule and often ... making it all but impossible to peer into the ... those problems may soon be a thing of the ...
(Date:4/18/2014)... Durham, NC Seeds that sprout as soon as they,re ... plants need to be more careful. In the wild, a ... rainy day would risk disaster. More than just an insurance ... out that seed dormancy has long-term advantages too: Plants ... give rise to more species, finds in a team of ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... antibiotic used to boost organ survival in transplant ... the heart against tissue damage following acute heart ... Journal of Molecular and Cellular Cardiology, the official ... researchers demonstrated for the first time that pretreatment ...
... to change their spots, but corals can change their skeletons, ... composition of the seawater around them. , That's the startling ... in the July issue of the journal Geology. , ... the first known case of an animal altering the composition ...
... University in St. Louis and their collaborators from Taiwan ... varieties and have determined that the crop was domesticated ... Jason Londo, Washington University in Arts & Sciences biology ... Washington University Spencer T. Olin Professor of Biology in ...
Cached Biology News:New study shows antibiotic may protect the heart 2Corals switch skeleton material as seawater changes 2Corals switch skeleton material as seawater changes 3Biologists find regions of rice domestication 2
... JMP 6 delivers enhanced statistics and ... and quality improvement managers. As an ... JMP 6 simplifies statistics for novice ... needed by experts. It offers a ...
... F1 antigen, Monoclonal Antibody, Unconjugated ... Use at an assay dependent dilution. ... dilution. WB: Use at an assay ... kDa. Not tested in other applications. ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: